Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, effective February 1, 2025, Nova Scotia is publicly funding Pluvictotm (lutetium (177Lu) vipivotide tetraxetan ...

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, effective 1, 2025, Nova Scotia is publicly funding Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan injection), providing ...

If the scientists could very precisely measure the proportions of lutetium and halfnium in moon rocks compared to other ...

President Trump announced that the United States plans to impose additional tariffs on imports from Canada, China, and Mexico ...

During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

The poster titled “ Preclinical and Translational Pharmacokinetics of GD2-SADA, a Self-Assembling and Disassembling (SADA) Bispecific Fusion Protein for Pretargeted Radioimmunotherapy (PRIT)” ...

ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...

ORLANDO, FL / / January 31, 2025 / RedChip Companies will air interviews with Venu Holding Corporation ('VENU') (NYSE American:VENU) and ASP Isotopes (Nasdaq:ASPI) on the RedChip Small Stocks, Big ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

ONTARIO—The Ontario government is connecting more people to care by being the first Canadian jurisdiction to publicly fund and administer PLUVICTO, a new treatment for advanced-stage prostate cancer, ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...